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Edited by Judit Ova´diAbstract Topoisomerase II plays an essential role in the segre-
gation of chromosomes during cell division. It is also a major
component of the nuclear matrix. Proteins that interact with
and regulate this essential enzyme are of great interest. To inves-
tigate the role of proteins interacting with the N-terminal domain
of the Saccharomyces cerevisiae topoisomerase II, we used a
yeast two-hybrid protein interaction screen. We identiﬁed an
interaction between the catalytic domain of the yeast protein ki-
nase 1 enzyme (Pkc1) and the N-terminal domain of the S. cere-
visiae topoisomerase II. The S. cerevisiae Pkc1 is the homologue
of the mammalian calcium dependent PKC.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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two-hybrid1. Introduction
Topoisomerase II is required for the viability of all eukary-
otic cells. It plays important roles in DNA replication, recom-
bination, chromosome segregation and the maintenance of the
nuclear scaﬀold. Saccahromyces cerevisiae has proved a power-
ful system for understanding the functions of topoisomerase II
in cell division and DNA repair (for reviews see [1–4]) . There
are two human isoforms of topoisomerase II designated a [5]
and b [6,7]: which show distinct pattern of expression during
the cell cycle, having diﬀerent nuclear localisation and tissue
speciﬁc expression. Our analysis of the two human enzymes,
using S. cerevisiae as an in vivo system, has shown no func-
tional diﬀerences between the two enzymes in their ability to
support chromosomal segregation [8]. However, we were able
to express the human isoforms in S. cerevisiae allowing the rel-
ative sensitivity of the two enzymes to various cytotoxic agents
to be assessed [9]. Amino-acid sequence alignment between hu-
man and S. cerevisiae type II topoisomerases shows that the
proteins are highly conserved except within the C-terminal do-
main and at the extreme N-terminal regions of the protein [10].
The activity of topoisomerase II is regulated by its phos-
phorylation state. The C-terminal domain is the major target
for regulation by phosphorylation, and it is thought that this
domain may act in a negative manner: the activity of topoiso-
merase II being increased when this domain is phosphorylated*Corresponding author. Fax: +44 151 794 6825.
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doi:10.1016/j.febslet.2005.11.075[11,12]. It has been proposed that the C-terminal domain of
topoisomerase II is also involved in direct speciﬁc interactions
with other proteins required to eﬀect chromosome segregation.
Two proteins that interact with the C-terminal domain of the
S. cerevisiae topoisomerase II have been isolated using the
yeast two-hybrid cloning system. These proteins, Sgs1p, a
eukaryotic homolog of E. coli RecQ [13] and Pat1 a 90 kDa
proline and glutamine rich protein [14] are required, together
with topoisomerase II, for faithful chromosome segregation
and partitioning. The C-terminal domain of topoisomerase II
has been well studied however little is known about the N-ter-
minal domain of the topoisomerase II.
Proteins that interact with particular regions of topoisomer-
ase II have enabled particular functions to be assigned to that
region. Therefore in this paper we describe the use of a yeast
two-hybrid cloning screening strategy to identify proteins that
interact with the N-terminal domain of the S. cerevisiae topo-
isomerase II. Using this approach we have identiﬁed an inter-
action with the catalytic domain of the S. cerevisiae protein
kinase 1 enzyme (Pkc1). Pkc1 is the homologue of the mamma-
lian calcium dependent PKC [15], which belong to the group of
serine/threonine kinases characterized by a high level of
homology in their catalytic domains and cysteine-rich regions
[16]. We propose that this interaction plays an important role
in the thermal stress response pathway.2. Experimental procedure
2.1. Yeast strains
The following strains were used:
BJ201, pHT173 (Schizosaccharomnes pombe TOP2/URA-ARS/
CEN)MATa ura3 trp1 leu2 his3 pep4::HIS3 prb1D can1 topoisomerase
II::TRP1 GAL;} Jensen et al. [8].
JJ300 top2-4 leu2 ura3 ade2 rDNA::ADE2;}
EGY48: MATa his3 trp1 ura3-52 lex(LEU2)
8420:MATa/MATa leu-3/leu-112 ade2-1/ade2-1 his3-11/his3-15 ura3/
ura3 trp1-1/trp1-1 canr 1–100.
All media and transformations were as described in Current Proto-
cols in Molecular Biology [17].
E. coli strains. XL1-Blue (Stratagene).
2.2. Plasmids
pYES (Invitrogen), YCp50 and pBluescript SKII (Stratagene).
The yeast plasmids used for the two-hybrid screen: pJG4-5 (library),
pEG202 (lex A fusion DNA binding domain) and pSH1834 (lacZ re-
porter plasmid) are described [17].
The plasmid plexNtop3-310 and the plasmid plexNtop1–310YG
were constructed using PCR generated fragments which encoded resi-
dues 3–310 and 1–310, respectively, of the N-terminal domain ofblished by Elsevier B.V. All rights reserved.
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cerevisiae 8420 genomic DNA using Vent polymerase (New England
Biolabs) and the forward primer 5 0 ATG GAT CCA AAC TGA
ACC GGT AAG CGC C 3 0 and the reverse primer 5 0 ACC ACC
CAT GGT AGT TGC AAT 3 0 using standard PCR conditions. The
fragment Ntop1–310YG was ampliﬁed from pYT0300 plasmid DNA
using the proof reading Vent polymerase (New England Biolabs)
and the forward primer 5 0 CGG GAT CCC GAT GTC AAC TGA
ACC GGT AAG CGC CTG TGG TAA ATA TCA G 3 0 and the re-
verse primer 5 0 ACC ACC CAT GGT AGT TGC AAT 3 0 using stan-
dard PCR conditions. The PCR fragments were ligated in frame with
the lexA gene into the BamHI/NcoI sites of pEG202.
The construct pNtop3–310Q was obtained from the DNA template
pNTOP3–310 by PCR mutagenesis using the primers 5 0 GGT TCT
GTT GAA ACT CAA CAG CAG CTG CAG TGG ATA TAC G
3 0 and 5 0 C GTA TAT CCA CTG CAG CTG CTG TTG AGT
TTC AAC AGA ACC 3 0 and the Taq polymerase Pfu from (Strata-
gene) using standard PCR conditions. After digesting the PCR with
the restriction enzyme DpnI , 2 ll of the PCR were transformed into
supercompetent cells XL1 blue from Stratagene.
The plasmids plexNTOP155–307 and plexNTOP3–p37 were con-
structed by cloning the TOP 2 gene restriction fragments EcoRI–
EcoRI and BamHI–PvuII encoding the residues 155–307 and 3–37,
respectively, in frame with lexA gene into the EcoRI or BamHI/NcoI
restriction sites of pEG202, respectively. To generate a blunt end to
accommodate the PvuII site, the NcoI restriction site of pEG202 was
ﬁlled-in using Klenow polymerase.
The plasmid pYT0300 contains the wild-type S. cerevisiae TOP2
gene under the control of the TPI promoter [8]. The plasmid pY-
T0300YG was constructed by cloning the BamHI/NotI topoisomerase
II fragment from plexNtop1–310YG into pYT0300 lacking the 5 0
end BglII/NotI of the wild type yeast TOP 2 gene (this reconstitute a
full length S. cerevisiae top2 gene which is mutated so it can no longer
bind Pkc1).
The plasmid plexHbNTOP3–232 was produced by a two steps sub-
cloning strategy. A 1.7 kb MscI restriction fragment containing the
5 0end of the human topoisomerase II b gene was cloned into pBlue-
script. Then a sub-restriction fragment BamHI/NsiI was cloned in
frame with the lexA gene into pEG202.
The plasmid plexHaNTOP1–205 was constructed using a PCR ap-
proach. The fragment HaNTOP1-205 was ampliﬁed from pHT300
plasmid DNA [8] using the proof reading vent polymerase (New Eng-
land Biolabs) and the forward primer 5 0 ATG GAT CCT CAC CAT
GGA AGT GTC ACC ATT GC 3 0 and the reverse primer 5 0 TTC
CAT CTC ACC AGC TCT TCC 3 0 using standard PCR conditions.
The PCR fragment was ligated in frame with the lexA gene into
pEG202.
All clones were conﬁrmed by sequencing.
Other yeast plasmids were a kind gift from Drs. P.E. Sudbury and
K. Duﬀy, the functionally expressed proteins of the plasmids are de-
noted by the gene names that follow the plasmid name:
pRho1 (Rho1),
pBCK 1–20 (BCK1/SLK1 high copy number),
pB289 (NHP6B), pB290(NHP6A),
pB305 (SLT2/MPK1),
pB309 (BCK1/SLK1),
pPCK1 (PKC1).
2.3. Yeast two-hybrid screen
The two-hybrid screen was performed essentially as described by
Gyuris et al. [18] and Zervos et al. [19] and Watt et al. [13]. The yeast
activation domain library that was used has been described previously
[13]; was transformed into the reporter strain EGY48, which had pre-
viously been transformed with plexNtop3–310 and pSH1834. Plasmids
were isolated from yeast which survived selection for leucine prototro-
phy and were blue on plates containing X-gal only when the medium
was supplemented with galactose.2.4. Mitotic viability assay
BJ201 cells were transformed with either pYT0300 or pYT0300YG.
The transformed cells were grown to mid-log phase in selective med-
ium at 30 C and replicate dilutions plated onto two sets of selective
plates. One set was incubated at 30 C and the other set was incubated
at 35 C. After two or four days of incubation, colonies on the two setsof plates were counted (three plates per strain/per dilution/per temper-
ature) and the relative plating eﬃciency ((colonies at 30 C/colonies at
35 C) · 100) was calculated.2.5. Heat shock viability
Yeast cells heat shock. An overnight culture grown in selective media
–LEU was diluted into YPD media and grow until OD = 1 at 600 nm.
Cells were then washed in H2O and resuspended in –LEU media at
106 cells/ml. Some cells were incubated at 37 C for 30 min then at
50 C for 5–20 min and some cells were directly incubated at 50 C
for 5–20 min. 100 ll of 1/100 dilution were then plated onto –LEU
media and incubated at 30 C for 2 days.2.6. Immunoprecipitations and Western blots
Western blots and immunoprecipitation from yeast extracts were
performed as described by Watt et al. [13]. The anti-Myc (9E10) and
anti-HA (12CA5) antibodies were a kind gift from Prof. Ian Hickson.
The anti-human topoisomerase II a antibody came from LabVision,
UK. Protein concentrations were estimations using the Bio-Rad pro-
tein assay kit.2.7. Topoisomerase II assay
The topoisomerase II assay was carried out according to the manu-
facturer’s speciﬁcations (Topogen). The diﬀerence being that the yeast
strains were broken open by vortexing in the presence of glass beads
(Sigma) at 4 C. Protein concentrations were estimations using the
Bio-Rad protein assay kit.3. Results
3.1. Yeast two-hybrid screening with the N-terminal
topoisomerase II domain
To identify proteins that interact with the N-terminal do-
main of the yeast topoisomerase II, a two-hybrid cloning strat-
egy was used, the bait construct being, pLexNTOP3–310,
Fig. 1A. Ninety thousand transformants were obtained and se-
lected for the ﬁrst part of the sorting procedure, gal depen-
dence and lacZ phenotype. One hundred and one colonies
survived the selection for leucine and were blue on X-gal con-
taining plates. These represented three diﬀerent genes, one of
which was PKC1, the others were ATE1 and HAP1.
We focussed our interest on the clones expressing the PKC1
gene (1.5 kb smallest fragment). The PKC1 fragment 700–2006
encodes most of the C2 domain (the very 5 0sequence for this
domain is not present within this region), all of the C1 domain
and part of the C1-Kinase linker region, amino acid 206–700
based on Accession No. P24583 amino-acid sequence. To con-
ﬁrm the interaction between topoisomerase II and Pkc1
in vivo, a myc-tagged topoisomerase II [13] was co-expressed
with the HA-tagged Pkc1 fragment encoded by pLexAD
PKC 206–700 in the yeast strain 8420 and proteins were immu-
noprecipitated using anti myc antibodies. The Western blot re-
vealed that the HA-tagged Pkc1 is co-immunoprecipitated
with the myc-tagged topoisomerase II under galactose induc-
tion (see Fig. 1C).3.2. Identiﬁcation of the domain of interaction
To determine the region of the yeast topoisomerase II that
interacts with Pkc1, the activation assay was repeated using
the constructs plexNTOP3–37 and plexNTOP155–307 de-
scribed in Fig. 1A. The PKC1 pLexADPKC206–700 construct
failed to activate transcription in the presence of a Topoiso-
merase II fusion protein containing amino acid 155–307
Fig. 1. Plasmid constructs used to test the interaction between Topoisomerase II and Pkc1. (A) Yeast and human Topoisomerase II constructs used
as bait in the two-hybrid assay. The result of the activation assay for each construct is indicated on the right of each construct. The sign + notiﬁes the
presence of an interaction and the sign  an absence of interaction. The last two line diagrams represent the full length Topoisomerase II gene
pYT0300 [8] and its derived pYT0300YG used to test the eﬀect of the loss of interaction in vivo. (B) Multiple alignment of the ﬁrst 155 amino acids of
the yeast TopII, 176 amino acid or 191 amino acid of the human Topoisomerase II a or b. The dot represents a space and a – an amino acid
homologoue. (C) Western blot analysis of imunoprecipitations to test the interaction between Topoisomerase II and Pkc1. 842 cells were
cotransformed with plasmids pTopII-myc and pLexAD PKC 206-700. Yeast cells were grown overnight in liquid media gly-UT, diluted and grown
until they reached an OD600 of one, the control aliquots were then grown for a further 4 h in gly-UT media, Lane 1 (total cell extracts, TE, no
immunoprecipitation), Lane 2 (Immunoprecipitations (IP)) were carried out on the yeast cell extract using an anti-myc antibody to pull down the
myc-tagged topoisomerase II and any associated proteins, speciﬁcally the Pkc1 fragment fused to HA. Aliquots of the yeast cells were changed from
gly-UT media to gal-UT media, to induce protein production, and grown for a further for 4 hours, Lane 3 (total cell extracts, TE, no
immunoprecipitation) and Lane 4 (immunoprecipitation (IP) using an anti-myc antibody to pull down the myc-tagged topoisomerase II). The blot
was probed with an anti-HA antibody to identify the Pkc1 fragment fused to HA. The molecular weight of the Pkc1-HA fusion peptide is
approximately 28 kDa. (D) Western blot analysis of topoisomerase II expression levels. The topoisomerase II deletions strain BJ201 containing
pYTO300 or pYT0300YG was grown overnight in YPD at 25 and 35 C. Total cell extracts (protein concentrations were estimations using the Bio-
Rad protein assay kit and equal amounts loaded onto each lane) were run on SDS–PAGE gels, blotted on to nitrocellulose and the blots probed with
an anti-human topoisomerase IIa antibody, which cross reacts with yeast topoisomerase II (Topo II).
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the presence of the Topoisomerase II fusion containing amino
acid 3–37, (pLexNTOP3–37, Fig. 1A).The amino-acid sequences of the yeast and human type II
topoisomerases display a high degree of similarity. To investi-
gate the possibility of the N-terminal domain of the human
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ried out a two-hybrid assay using the N-terminal regions of
the two human topoisomerase II isoforms as bait (plexHaN-
TOP1–205 and plexHbNTOP3–232) and the pLex-
ADPKC206–700 construct as the activator. The PKC1
construct pLexADPKC206–700 failed to activate transcription
with either of the two human Topoisomerase II a or b con-
structs containing amino acid 1–205 and 3–232 (Fig. 1A),
respectively, suggesting that the interaction might be speciﬁc
for S. cerevisiae Pkc1 and S. cerevisiae type II topoisomerase.
A multiple alignment of the N-terminal domain of the yeast
and human Topoisomerase II is presented in Fig. 1B. The
N-terminal domain of these Topoisomerase II proteins shows
a high degree of similarity with the exception of the yeast
Topoisomerase II amino acid 8–11 and 34–36. Based on these
observations, we made two new construct that contains amino
acids 1–310 of the yeast N-terminal Topoisomerase II, where
the amino acid 9 and 10 were substituted, Ser to Tyr and
Asp to Gly; pLexNtop1–310YG, and amino acid 36 Glu to
Gln (Fig. 1A). Using these new constructs as bait, interaction
with Pkc1 was still detected with the mutation 36 Gln but not
detected with the 9/10 Tyr/Gly mutation. Therefore, Pkc1
probably interacts within a 3–37 amino-acid region of the yeast
Topoisomerase II speciﬁcally involving amino acids, 9 and/or
10.
3.3. Phenotypic analysis of the BJ201 pYT300YG strain
The components [16] and mutant phenotypes [20] of the S.
cerevisiae Pkc1-mediated MAP kinase cascade are well charac-
terized. To assess the eﬀect of possibly disrupting the proposed
interaction between Pkc1 and topoisomerase II the strain
BJ201 (DTop2, deletion strain) carrying the plasmid pHT173
(the S. pombe topoisomerase II gene, allowing viability) wasFig. 2. Testing the phenotype of the topoisomerase II deletions strain BJ201
containing pYTO300 or pYT0300YG was streaked on to various test min
(B) 35 C, (C) 35 C with 10% sorbitol, (D) 30 C with 10 mM caﬀeine, (E) 30transformed with either pYT0300 (wild type S. cerevisiae topo-
isomerase II gene) or pYT0300YG (mutated S. cerevisiae topo-
isomerase II gene) and the incumbent plasmid pHT173 was
eliminated by growing the yeast on 5-FOA [20]. The relative
levels of topoisomerase II expression from the two plasmids
was tested at 25 and 35 C, see Fig. 1d. Vegetative growth
was tested on various media at 30 and 35 C, see Fig. 2. The
strain expressing the mutated topoisomerase II demonstrated
a temperature sensitive phenotype at when grown 35 C which
was sorbitol suppressible. The strain also showed sensitivity to
NaCl and exquisite sensitivity to caﬀeine. The phenotype ob-
served is similar to that seen for a pkc1 mutant [21].
3.4. Mitotic viability
To gain a more accurate measure of the mitotic viability of
the yeast cells containing the mutated topoisomerase II gene,
pYT0300YG dilutions of early log phase cells were plated on
to minimal media and incubated at 30 and 35 C and com-
pared with yeast containing the wild type topoisomerase II
gene, pYT0300. At 30 C the strain carrying pYT0300YG
was only 53% viable when compared with the strain carrying
pYT0300 and the strain containing pYT0300YG was only
17.5% viable at 35 C when compared to itself at 30 C.
3.5. Complementation of the Pkc1 like defects by over
expression of Rho1 pathway members
To test whether the heat sensitivity observed when the topo-
isomerase II function is supplied by pYTO300YG is associated
with the MAP kinase pathway, we transformed BJ201 (pY-
TO300YG) with various plasmids that expressed components
of the MAP pathway; pRho1 (Rho1), pKPC1 (Pkc1), pB309
(Bck1/Slk1), pBCK1-20 (Bck1 overexpresser), pB305 (Mpk1/
Slt2), pB289 (Nhp6B), pBB290 (Nhp6A). Plasmids encodingcontaining pYT0300YG. The topoisomerase II deletions strain BJ201
imal media, (with the required amino acid supplements): (A) 30 C,
C with NaCl and (F) a diagram identifying the position of the strains.
Fig. 4. Growth curves showing temperature sensitivity. An overnight
culture of BJ201 cells transformed with either pYT0300 or pY-
T0300YG grown overnight in selective media –LEU, diluted into YPD
media and grow until OD = 1 at 600 nm. Cells were then washed in
H2O and resuspended in –LEU media at 10
6 cells/ml. Some cells were
incubated at 37 C for 30 min then at 50 C for 5–20 min and some
cells were directly incubated at 50 C for 5–20 min. To determine the
viability, dilutions were plated onto –LEU media and incubated at
30 C for 2 days and then the cell numbers counted.
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complemented the temperature sensitive phenotype. However,
plasmids encoding Pkc1, Nhp6A or Nhp6B did not comple-
ment this defect. See Fig. 3 for plate growth assay examples.
3.6. Is the topoisomerase II–Pkc1 interaction involved in
thermotolerance
Pkc1 is an important part of the regulated MAP kinase path-
way for induced thermotolerance and the protein kinase is
strongly activated by mild heat shock. This activation is sus-
tained during growth at high temperature and is dependent
on the function of pathway components proposed to function
upstream of Mpk1, including Pkc1 [22].
To assess the possibility of a role in thermotolerance involv-
ing the interaction between Topoisomerase II and Pkc1, BJ201
yeast cells containing either pYT0300 or pYT0300YG were
grown at 30 C then shifted to 50 C, a pretreatment at
37 C then a shifted to 50 C was also carried out. The cells
were then diluted, plated and the surviving cells counted.
Fig. 4 shows higher sensitivity of the mutant Topoisomerase
II to the temperature shift, particularly at 5 min 50 C treat-
ment with out pretreatment. The mutant is also slightly less
eﬃcient in the acquisition of thermotolerance induced by the
pretreatment at 37 C.
3.7. What is the aﬀect of disrupting the Pkc1–Topoisomerase II
interaction on the activity of topoisomerase II?
The activity of topoisomerase II is essential for yeast viabil-
ity. As shown above, elevation of the temperature has an eﬀect
on both cell growth and viability in the strain carrying the mu-
tated topoisomerase II when compared to a strain carrying a
wild type gene. To assess the activity of the topoisomerase II
enzyme with in these two strains, they were grown overnight
at 25, 30 and 35 C in YPD (rich media). Protein extracts were
generated from the two strains, at each temperature and the
amount of protein estimated. The protein concentration, per
temperature pair, was equalized using the extraction buﬀer
to ensure that there was no diﬀerence in salt concentrations.
Equal volumes (equal protein concentrations) were then used
in the topoisomerase II assay to decatenate the kDNA sub-
strate. The marker 1 lane, in Fig. 5 shows nicked and circular
decatenated kDNA, the expected products of the topoisomer-
ase II decatenation assay. These bands can be seen clearly
when extracts, from the strain carrying the wild type topoiso-
merase II gene are used in the assay, all three temperatures,
there is also an increase in activity with increasing amounts
of protein (a plateau of activity may be reached in the lanes
with 1 and 2 ll of cell extract). It is interesting to note that
some concatomers of nicked kDNA (observable as bandsFig. 3. Complementation of BJ201 pYT0300YG with various components of
containing pYTO300YG (on its own blank triangle), or pYTO300YG and
kinase pathway. (A) 30 C, (B) 35 C and (C) diagram showing the strain conabove the nicked and circular decatenated kDNA) appear in
the lanes where the cell extracts were generated from the yeast
grown 30 and 35 C. The results from the cell extracts gener-
ated from the train carrying the mutated topoisomerase II
are very diﬀerent, very little decatenation activity can be
observed, however a lot of concatomers of nicked kDNA are
observed.4. Discussion
In this study, using the two-hybrid assay, we have demon-
strated that amino acids 3–37 of the N-terminal region of S.
cerevisiae topoisomerase II are necessary and suﬃcient to
interact with the catalytic domain C1 of the S. cerevisiae
Pkc1. S. cerevisiae Pkc1 is essential for both cell cycle and cell
growth with cells arresting at the G2–M transition [23]. It is
interesting to note that, in studies involving human proteins,the MAP kinase pathway. The topoisomerase II deletions strain BJ201
another plasmid that allows the expression of a member of the MAP
taining the various plasmids and how they were streaked on the plates.
Fig. 5. The activity of the topoisomerase II enzyme extracted from
BJ201 containing a wild type or mutated topoisomerase II. Cultures of
BJ201 cells transformed with either pYT0300 or pYT0300YG grown
overnight at 25, 30 and 35 C. Protein extracts were generated from the
two strains, at each temperature and the amount of protein estimated.
The protein concentration, per temperature pair, was equalized using
the extraction buﬀer. Equal volumes (equal protein concentrations)
were then used in the topoisomerase II assay to decatenate the kDNA
substrate. The marker 1 lane, in ﬁgure 5 shows nicked and circular
decatenated kDNA marker lane 2 shows linear kDNA. Assays
containing cell extract 0.00, 0.25, 0.50, 1.00 and 2.00 ml from BJ201
pYTO300 are in lanes 3-7 and assays containing cell extract 0.00, 0.25,
0.50, 1.00 and 2.00 ml from BJ201 pYTO300YG are in lanes 8–12.
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using the two-hybrid analysis and that in all cases the binding
is through the PKC regulatory domain [24]. In S. cerevisiae,
the catalytic domain C1 of Pkc1 has been shown to interact
with Rhop1 [25]. Wells et al. [26] demonstrated the existence
of a functional link between PKC and cell cycle control in that
human topoisomerase II alpha is phosphorylated by PKC in a
cell-cycle phase-dependent manner. Potentially this means
there is a conserved mechanism that links signal transduction
pathways and cell cycle machinery in S. cerevisiae. Kamada
et al. have shown that the Pkc1 regulated pathway is important
for induced thermotolerance [22]. Further compelling evidence
to support this interaction comes from a recent paper by Denis
and Cyert [27] which shows Pkc1 has two NLSs located within
the interdomain region, can be found in the nucleus and that it
and that it is associated with mitotic spindles. They also pro-
pose that it enters the nucleus in response to a speciﬁc stimulus.
A role in bud emergence has also been described [28]. pkc1
deletion mutants are sensitive to heat and caﬀeine; this pheno-
type can be suppressed by growth on a media containing an os-
motic stabilizing agent such as sorbitol [21].
The mutation of the amino acids 9 and 10 of the N-terminal
region of the S. cerevisiae topoisomerase II results in the loss of
the binding with Pkc1, as determined by the yeast two-hybrid
assay (see constructs in Fig. 1). When this change was incorpo-
rated into full-length topoisomerase II genes and expressed in
an S. cerevisiae strain BJ201 (lacking the genomic copy oftopoisomerase II), the mutated gene supports almost normal
mitotic function at 30 C as shown Figs. 2 and 3. However,
the BJ201 strain, in which the mutated form of the topoisomer-
ase II is being expressed, is sensitive to temperature. If the
strain is plated out and incubated at 35 C it is only 17.5% via-
ble as compared to the 79.5% viability of BJ201 expressing
wild type S. cerevisiae topoisomerase II gene, from the parent
plasmid. The complementation studies with plasmids encoding
Pkc1, NHP6 A&B did not restore the normal phenotype this is
further evidence that the defect is speciﬁc to Pkc1 rather than
the MAP kinase pathway because over expression of NHP6
A&B have previously been shown to suppress deletions of
Bck1 and Mpk1 [29].
When complementation for the S. cerevisiae topoisomerase
II gene is provided by human topoisomerase IIa, slow growth
phenotype is also observed (data not shown). We have shown
by the two-hybrid assay that the N-terminal human topoiso-
merase IIa does not interact with the yeast pkc1 (Fig. 1). To-
gether, this provides further evidence that the Topoisomerase
II–Pkc1 interaction is important in S. cerevisiae. Furthermore,
upon heat shock at 50 C for 5 min the BJ201 pYT0300YG
strain is only 37% viable compared with 88% viability for the
BJ201 pYT0300 strain. Suppression of the TS phenotype is
achieved by expression of a number of MAP kinase pathway
genes, but notably not Pkc1, indicating that the interaction be-
tween the two proteins functions as part of the MAP kinase
pathway. The topoisomerase II activity assay clearly demon-
strates that the enzyme from the strain carrying the mutated
topoisomerase II has a reduced or altered activity. Concat-
omers of nicked kDNA are also observed in a topoisomerase
II assay if too much NaCL or KCl is present in the assay buf-
fer, which is not the case here but again points to an instability
of the enzyme. These data suggest that the role of the Pkc1 reg-
ulated pathway in thermotolerance is at least in part dependent
on an interaction with topoisomerase II.
There are formal possibilities that the mutation of the topo-
isomerase II prevents the binding of another important protein
or that it has cause the topoisomerase II enzyme to become
more unstable and as this that is what causing the observed
phenotypes. However, we propose that in response to heat
and stress, Pkc1 is playing a role in topoisomerase II stability
by interacting directly with topoisomerase II and activating the
formation of chromosomal DNA loops as proposed by [30]. A
role for Pkc1 which involves DNA metabolism and its eﬀect on
mitotic recombination [31] has also been proposed. These
functions would act via an alternative Pkc1 pathway to that
used in the regulation of cell lysis. This alternative pathway
probably more in keeping with a role identiﬁed by the interac-
tion between topoisomerase II and Pkc1. Pkc1 depleted cells
display a uniform cdc phenotype where the cells arrest after
DNA replication but before mitosis with a small bud [21]. This
is eﬀectively the G2/M boundary where topoisomerase II is re-
quired. This also supports the possibility that topoisomerase II
is part of the RSC chromatin-remodeling complex and is reg-
ulated by Pkc1 and ﬁts with the function of topoisomerase II
as part of the nuclear scaﬀold.
We have demonstrated an interaction between the S. cerevi-
siae topoisomerase II and Pkc1 and that this interaction has a
functional importance in the response of a stress induced by a
number of factors, heat caﬀeine and NaCl. It also lends further
support for an alternate Pkc 1 function possibly involved in
chromosome remodeling.
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